Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-22T14:43:58.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury

Published online by Cambridge University Press:  01 February 2008

F. Lombardi
F. Lombardi*
Affiliation:
Riabilitazione Intensiva Neurologica, Ospedale “S. Sebastiano”, Correggio (RE), Italy
*
Correspondence to: Francesco Lombardi, Riabilitazione Intensiva Neurologica, Ospedale “S. Sebastiano”, Via Mandriolo Superiore 11, 42015 Correggio (RE), Italy. E-mail: [email protected]; Tel: +39 522 630394; Fax: +39 522 630332
Get access

Summary

Neurobehavioural sequelae of traumatic brain injuries require an appropriate/effective pharmacological response in that they represent an important cause of disability. In this field, there is no evidence that reaches the level of a standard: there are guidelines on the use of methylphenidate, donepezil and bromocriptine for the treatment of cognitive disturbances, for the non-use of phenytoin and for the use of β-blockers for controlling aggressiveness. Resolving a single symptom is not relevant in a rehabilitation project if it is not in the context of a more complex picture of neurobehavioural recovery, in which the positive and negative effects of every therapeutic choice are considered. For example, phenytoin could be used for the positive control of epileptic crises but is not advised since it impedes the recovery of cognitive functions in general. Analogous effects not yet identified may concern benzodiazepine, neuroleptics and other sedatives usually prescribed in cases of cranial trauma. Psychotropic drugs are considered to be able to influence the neuronal plasticity processes. Studies on animals have shown that the administration of D-amphetamine combined with sensorial-motor exercise produces the steady acceleration of motor recovery, which acts as a catalyst to the neurological recovery process. On the other hand, α1-NA receptor antagonist drugs produce negative effects; these include clonidine (antihypertension) and haloperidol (neuroleptic). Studies need to be carried out to evaluate the effectiveness of particular drugs. These studies need to focus not only on the disappearance of symptoms but also on the positive and negative effects on overall rehabilitation and on the neurobiological recovery of the patient.

Keywords

BRAIN INJURYPSYCHOSISTRAUMADEPRESSIONLONG-TERM EFFECTSCOGNITION DISORDERS
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 25 , Issue S42 , February 2008 , pp. 131 - 136
Copyright
Copyright © European Society of Anaesthesiology 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Fann, JR, Katon, WJ, Uomoto, JM et al. . Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Am J Psychiatry 1995; 152: 1493–1499.Google ScholarPubMed
2.Prigatano, GL. Personality disturbances associated with traumatic brain injury. J Consult Clin Psychol 1992; 60: 360–368.CrossRefGoogle ScholarPubMed
3.Warden, DL, Gordon, B, McAllister, TW et al. . Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. Neurobehavioral Guidelines Working Group. J Neurotrauma 2006; 23: 1468–1501.CrossRefGoogle Scholar
4.Koponen, S, Taiminen, T, Portin, R et al. . Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry 2002; 159: 1315–1321.CrossRefGoogle ScholarPubMed
5.Gentilini, M, Nichelli, P, Schoenhuber, R. Assessment of attention in mild head injury. In: Levin, H, Eisenberg, H, Benton, A, eds. Mild Head Injury. New York, USA: Oxford University Press, 1989: 163–175.Google Scholar
6.Raskin, SA, Mateer, CA. Neuropsychological Management of Mild Traumatic Brain Injury. New York, USA: Oxford University Press, 2000.Google Scholar
7.Lezak, MD. Neuropsychological Assessment, 3rd edn. New York, USA: Oxford University Press, 1995.Google Scholar
8.McAllister, TW. Neuropsychiatric Sequelae of Head Injuries. Psychiatr Clin North Am 1992; 15: 395–413.CrossRefGoogle ScholarPubMed
9.Wolf, AP, Gleckman, AD, Cifu, DX et al. . The prevalence of agitation and brain injury in skilled nursing facilities: a survey. Brain Inj 1996; 10: 241–245.CrossRefGoogle ScholarPubMed
10.Tateno, A, Jorge, RE, Robinson, RG. Clinical correlates of aggressive behavior after traumatic brain injury. J Neuropsychiatry Clin Neurosci 2003; 15: 155–160.CrossRefGoogle ScholarPubMed
11.Arciniegas, DB, Topkoff, J, Silver, JM. Neuropsychiatric aspects of traumatic brain injury. Curr Treat Options Neurol 2000; 2: 169–186.CrossRefGoogle ScholarPubMed
12.Kudoh, A, Takase, H, Takahira, Y, Takazawa, T. Postoperative confusion increases in elderly long-term benzodiazepine users. Anesth Analg 2004; 99: 1674–1678.CrossRefGoogle ScholarPubMed
13.Paterniti, S, Dufouil, C, Alperovitch, A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J Clin Psychopharmacol 2002; 22: 285–293.CrossRefGoogle ScholarPubMed
14.Golombok, S, Moodley, P, Lader, M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 365–374.Google ScholarPubMed
15.Stewart, SA. The effect of benzodiazepines on cognition. J Clin Psychiatry 2005; 66: 9–13.Google ScholarPubMed
16.Mintzer, MZ, Griffiths, RR. Drugs, memory and metamemory: a dose-effect study with lorazepam and scopolamine. Exp Clin Psychopharmacol 2005; 13: 336–347.CrossRefGoogle ScholarPubMed
17.Barker, MJ, Greenwood, KM, Jackson, M, Crowe, SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37–48.CrossRefGoogle ScholarPubMed
18.Morrens, M, Wezenberg, E, Verkes, RJ et al. . Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol 2007; 27: 15–21.CrossRefGoogle ScholarPubMed
19.Woodward, ND, Purdon, SE, Meltzer, HY, Zald, DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007; 89: 211–224.CrossRefGoogle ScholarPubMed
20.Meltzer, HY, McGurk, SR. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233–255.CrossRefGoogle ScholarPubMed
21.Keefe, RS, Seidman, LJ, Christensen, BK et al. . Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985–995.CrossRefGoogle ScholarPubMed
22.Albensi, BC, Janigro, D. Traumatic brain injury and its effects on synaptic plasticity. Brain Inj 2003; 17: 653–663.CrossRefGoogle ScholarPubMed
23.Gualtieri, CY. Review: pharmacotherapy and neurobehavioural sequelae of traumatic brain injury. Brain Inj 1988; 2: 101–129.CrossRefGoogle ScholarPubMed
24.Haig, AJ, Ruess, JM. Recovery from vegetative state of six months duration associated with Sinemet (levodopa/carbidopa). Arch Phys Med Rehabil 1990; 71: 1081–1083.Google ScholarPubMed
25.Matsuda, W, Sugimoto, K, Sato, N et al. . A cause of primary brain stem injury recovered from persistent vegetative state after L-dopa administration. No To Shinkey 1999; 51: 1071–1074.Google ScholarPubMed
26.Feeney, DM, Gonzales, A, Law, WA. Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex injury. Science 1982; 217: 855–857.CrossRefGoogle ScholarPubMed
27.Feeney, DM, Weisend, MP, Kline, AE. Noradrenergic pharmacotherapy, intracerebral infusion and adrenal transplantation promote functional recovery after cortical damage. J Neural Transplant Plast 1993; 3: 199–213.CrossRefGoogle Scholar
28.Hovda, DA, Feeney, DM. Amphetamine and experience promote recovery of function after motor cortex injury in the cat. Brain Res 1984; 298: 358–361.CrossRefGoogle ScholarPubMed
29.Goldstein, LB. Pharmacological approach to functional reorganization: the role of norepinephrine. Rev Neurol 1999; 155: 731–736.Google ScholarPubMed